Monday, September 26, 2022
    HomeHealthPrivate equity in autism care & a watershed FDA approval

    Private equity in autism care & a watershed FDA approval


    How did autism care grow to be a giant enterprise? Can gene remedy be worthwhile? And no matter occurred to that $40 billion merger?

    We cowl all that and extra this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Tara Bannow joins us to debate how personal fairness’s mounting curiosity in autism care has created an untenable scenario for a lot of dad and mom within the U.S. We additionally clarify the implications of Bluebird Bio’s long-awaited FDA approval, a controversial remedy for ALS, and the ups and downs of Merck’s reported curiosity in shopping for Seagen.

    For extra on what we cowl, right here’s the story on autism care; right here’s more on the private equity angle; right here’s the news on Bluebird; right here’s the latest on ALS; right here’s more on the future of mRNA; right here’s where you can find episodes of Color Code; right here’s where you can subscribe to the First Opinion Podcast; and right here’s our complete coverage of the Covid-19 pandemic.


    Remember to join on Apple Podcasts, Spotify, StitcherGoogle Play, or wherever you get your podcasts.

    And if in case you have any suggestions for us — subjects to cowl, visitors to ask, vocal tics to stop — you may e-mail [email protected].

    Source link

    Related articles

    Stay Connected


    Latest posts